Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy

HMGB1 is a member of highly conserved high mobility group protein superfamily with intracellular and extracellular distribution. Abnormal HMGB1 levels are frequently manifested in various malignant diseases, including breast cancer. Numerous studies have revealed the clinical value of HMGB1 in the diagnosis and therapy of breast cancer. However, the dual function of pro- and anti-tumor makes HMGB1 in cancer progression requires more profound understanding. This review summarizes the functions and mechanisms of HMGB1 on regulating breast cancer, including autophagy, immunogenic cell death, and interaction with the tumor microenvironment. These functions determine the strategies for the development of chemotherapy, radiotherapy, immunotherapy and combination therapies by targeting HMGB1 in breast cancer. Defining the mechanisms of HMGB1 on regulating breast cancer development and progression will facilitate the application of HMGB1 as a therapeutic target for breast cancer.

Automated summary

This review summarizes the clinical value of HMGB1 in diagnosis and therapy of breast cancer, as well as its functions and mechanisms in regulating breast cancer. It discusses the strategies of chemotherapy, radiotherapy, immunotherapy, and combination therapies by targeting HMGB1, and emphasizes the importance of HMGB1 as a therapeutic target in breast cancer treatment.